Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon N Edmiston

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 4, 2025
Association of Inherited Genetic Variants with Multiple Primary MelanomaDavid C Gibbs, Brittany M Small, Isidora Autuori, et al.
The Journal of Investigative Dermatology|August 27, 2017
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in MelanomaNancy E Thomas, Sharon N Edmiston, Peter A Kanetsky, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
The British Journal of Dermatology|July 12, 2025
Genomic loci and molecular genetic mechanisms for hidradenitis suppurativaK Alaine Broadaway, Quan Sun, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
JAMA Oncology|July 7, 2015
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary MelanomaNancy E Thomas, Sharon N Edmiston, Audrey Alexander, et al.
Pigment Cell & Melanoma Research|July 25, 2022
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL studyLi Luo, Ronglai Shen, Arshi Arora, et al.
JCO Precision Oncology|November 7, 2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic SignificanceKathleen Conway, Sharon N Edmiston, Amanda Vondras, et al.
Plos One|April 3, 2023
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanomaIrene Orlow, Keimya D Sadeghi, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2025
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III MelanomaJennifer M Wiggins, Qiao Zhang, Yian Zhang, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 4, 2025
Association of Inherited Genetic Variants with Multiple Primary MelanomaDavid C Gibbs, Brittany M Small, Isidora Autuori, et al.
The Journal of Investigative Dermatology|August 27, 2017
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in MelanomaNancy E Thomas, Sharon N Edmiston, Peter A Kanetsky, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
The British Journal of Dermatology|July 12, 2025
Genomic loci and molecular genetic mechanisms for hidradenitis suppurativaK Alaine Broadaway, Quan Sun, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
JAMA Oncology|July 7, 2015
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary MelanomaNancy E Thomas, Sharon N Edmiston, Audrey Alexander, et al.
Pigment Cell & Melanoma Research|July 25, 2022
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL studyLi Luo, Ronglai Shen, Arshi Arora, et al.
JCO Precision Oncology|November 7, 2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic SignificanceKathleen Conway, Sharon N Edmiston, Amanda Vondras, et al.
Plos One|April 3, 2023
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanomaIrene Orlow, Keimya D Sadeghi, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2025
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III MelanomaJennifer M Wiggins, Qiao Zhang, Yian Zhang, et al.
Pageof 4